ABSTRACT: Bone formation is a carefully controlled developmental process involving morphogen-mediated patterning signals that define areas of initial mesenchyme condensation followed by induction of cell-specific differentiation programs to produce chondrocytes and osteoblasts. Positional information is conveyed via gradients of molecules, such as Sonic Hedgehog that are released from cells within a particular morphogenic field together with region-specific patterns of hox gene expression. These, in turn, regulate the localized production of bone morphogenetic proteins and related molecules which initiate chondrocyte-and osteoblast-specific differentiation programs. Differentiation requires the initial commitment of mesenchymal stem cells to a given lineage, followed by induction of tissue-specific patterns of gene expression. Considerable information about the control of osteoblast-specific gene expression has come from analysis of the promoter regions of genes encoding proteins like osteocalcin that are selectively expressed in bone. Both general and tissue-specific transcription factors control this promoter. Osf2/Cbfal, the first osteoblast-specific transcription factor to be identified, is expressed early in the osteoblast lineage and interacts with specific DNA sequences in the osteocalcin promoter essential for its selective expression in osteoblasts. The OSF2/CBFAI gene is necessary for the development of mineralized tissues, and its mutation causes the human disease, cleidocranial dysplasia. Committed osteoprogenitor cells already expressing Osf2/Cbfa 1 must synthesize a collagenous ECM before they will differentiate. A cell:ECM interaction mediated by integrin-type cell-surface receptors is essential for the induction of osteocalcin and other osteoblast-related proteins. This interaction stimulates the binding of Osf2/Cbfa 1 to the osteocalcin promoter through an as-yet-undefined mechanism.
Introduction
An understanding of factors controlling gene expression in osteoblasts is of particular importance to dental researchers, both because of the fundamental role played by bone in the overall structure of oral tissues and because underlying principles involved in the control of osteoblasts will likely be relevant to other mineralized tissues such as dentin and cementum. The goal of this article is to provide a timely overview of current knowledge regarding early events in bone formation, with emphasis on the nuclear factors required for the selective expression of specific genes in osteoblasts and their regulation by extracellular matrix signals.
The Embryonic Patterning of Bone
There are two broad phases of tissue morphogenesis; an initial patterning phase, in which cells destined to form a given tissue are specified in time and space, and the subsequent induction of the necessary cellular phenotypes to produce the tissue of interest. These phases are not mutually exclusive. Rather, cells within a developing tissue can be viewed as altering the pattern of differentiation of their neighbors through a variety of signals mediated by diffusible factors, cell:extracellular matrix interactions, and direct cell:cell contact.
The patterning of bones and teeth has been the subject of several recent reviews and will not be extensively discussed in this article (Erlebacher et al., 1995 Figure 1 . Proposed steps in the osteoblast lineage implying recognizable stages of differentiation. All mesenchymal lineages are postulated to be derived from a common stem cell precursor (adapted from Aubin and Lui, 1996) . et al 1995. Johnson and Tabin, 1997) . However, a few common themes will be briefly outlined. The developing limb bud serves as a good example of the types of interactions necessary for skeletal morphogenesis (Tickle, 1995) . Early in limb development, an anterior/posterior axis is established which specifies the positions of bones such as the digits of the hand. This axis is determined by a group of cells in the posterior limb mesenchyme known as the Zone of Polarizing Activity (ZPA). These cells were identified by their ability, when transplanted to the anterior side of the limb bud, to induce a mirror-image duplication of skeletal elements. Sonic Hedgehog (Shh), a secreted protein, is the key inductive factor produced by the ZPA. The anterior/posterior asymmetry of limb bones is thought to be a reflection of the distribution of Shh throughout the limb bud as it is secreted from the ZPA. The primary targets of Shh are cells of the apical ectodermal ridge (AER) which, after Shh stimulation, produce Fibroblast Growth Factor 4 (FGF-4). stimulates Shh secretion in the mesenchyme underlying the AER. Shh also stimulates the homeobox gene, hoxd-13, which is required for normal limb patterning, and Bone Morphogenetic Protein 2 (BMP2), an inducer of cartilage condensation and subsequent bone formation. Thus, early limb morphogenesis is explained by a reciprocal pattern of inductive signals between underlying limb mesoderm and epithelium (AER) initiated by the asymmetric distribution of a signal originating from the ZPA. The overall result of these interactions is specification of the positional identity of skeletal elements well before the initiation of overt skeletogenesis. Recent evidence suggests that similar patterning events may take place in craniofacial bone formation and tooth morphogenesis (Satokata and Maas, 1994) .
The initial positional identity of skeletal precursors is defined by the pattern of expression of a family of transcription factors encoded by homeobox genes (reviewed in Erlebacher et al., 1995) . Consistent with the concept that they provide positional information, targeted inactivation, mutations, or ectopic expression of homeobox genes leads to deletion or addition of specific skeletal structures. For example, inactivation of the hoxa-2 gene results in deletion of the craniofacial elements derived from the second branchial arch and their replacement by elements derived from the first branchial arch (GendronMaguire et al., 1993) . The homeotic mutation does not, therefore, affect bone formation per se. Rather, it alters the type of bony structure to be formed at a given position. The initial pattern defined by the expression of homeobox genes is further modified by locally secreted factors such as BMPs. Certain homeotic genes, including members of the msx and dlx families, may also have direct Grigoriadis et al., 1988 Aubin and Lui, 1996; Triffit, 1996 al., 1992; Asahina et al., 1993; Wang et man et al., 1995) . In at least one case, the ivity of the BMP was irreversible (i.e., cells Isteoblastic properties even after the BMP indicating that the pluripotent mesenchybecome committed to the osteoblast lin- [1., 1993) . BMP-2 can also divert the differ-entiation pathway of C2C 12 myoblast from muscle to the osteoblast lineage (Katagiri et al., 1994) , although, in this study, effects of the BMP were reversible. Recent evidence suggests that glucocorticoids, a second class of compounds known to increase osteoprogenitors in marrow stromal cultures, may actually function by increasing BMP-6 synthesis (Boden et al., 1997) .
It is likely that BMPs are only one of several components necessary for the conversion of pluripotent stem cells to osteoprogenitors. For example, although BMP-2 clearly stimulates osteoblast differentiation in C3HIOTI/2 mesenchymal cells, it also stimulates formation of adipocytes and chondrocytes, with adipocytes being preferentially induced at low BMP concentrations and chondrocytes and osteoblasts favored at high concentrations . Interestingly, in this study, the activity of BMP-2 in stimulating formation of osteoblastic vs. adipogenic colonies could be perturbed by a number of humoral factors, including insulin, tumor-derived growth factor-3 (TGF-1), epidermal growth factor (EGF), leukocyte inhibitory factor (LIF), fibroblast growth factor-4 (FGF-4), and platelet-derived growth factor (PDGF). Other factors-such as the calcitropic hormone, 1,25-dihydroxyvitamin D3 stimulate induction of osteoblast characteristics, particularly in immature cells, and may, therefore, regulate progenitor formation (Franceschi et al., 1988; Gerstenfeld et al., 1996 (Gerstenfeld et al., 1987; Owen et al., 1990; Franceschi and Iyer, 1992; Ibaraki et al., 1992; McCauley et al., 1996) . A similar pattern of gene expression is also seen in vivo and in organ culture; osteoprogenitors adjacent to bone are highly proliferative and express low levels of bone-specific proteins, while secretory osteoblasts on the bone surface stop dividing and produce large amounts of bone-specific ECM (Strauss et al., 1990; Suva et al., 1993 ).
As will be discussed later in this article, a complete model for transcriptional regulation in osteoblasts must explain the conversion of mesenchymal stem cells to osteoprogenitors as well as the influences of cell proliferation and ECM synthesis on gene expression.
General Models for the Control of Tissue-specific Gene Expression
As noted above, the progression from uncommitted stem cell to osteoprogenitor and finally mature osteoblast and osteocyte is accompanied by specific changes in gene expression. A common theme in development is that specific transcription factors or groups of factors control the process of lineage commitment by selectively activating those genes to be expressed in the differentiated state. Several classes of tissue-specific transcription factors have been described, including the basic helix/loop/helix (bHLH) family involved in myogenic, myeloid, erythroid, and neuronal differentiation (Olson and Klein, 1994) , bHLH leucine zipper factors involved in adipocyte and liver differentiation (Tontonoz et al., 1993; Nishiyori et al., 1994) , orphan members of the steroid receptor superfamily such as HNF-4 involved in liver differentiation (Nishiyori et al., 1994) , and POU-domain factors involved in pituitary differentiation (Ingraham et (Weintraub et al., 1991 (myogenin, were subsequently cloned and shown to be involved in various steps in myoblast/myotube formation (Oldberg et al., 1986 (Olson and Klein, 1994) . Similarly, neuroD, a second type of bHLH protein, can convert presumptive epidermal cells into neural cells when its mRNA is injected into Xenopus embryos (Lee et al., 1995) . An example of the second approach is the isolation of the hepatocyte-specific factor, HNF-1. This transcription factor was identified in hepatocyte nuclear extracts by its ability to bind to an oligonucleotide containing a sequence in the ornithine transcarbamylase gene promoter previously shown to be essential for liver-specific expression (Nishiyori et al., 1994) . Although studies on osteoblast gene regulation have used both of the experimental approaches described above, investigators have achieved the greatest success in this area by focusing on specific gene promoters and associated nuclear factors. The osteocalcin gene and genes encoding the pro(xo(I) and proc2(I) chains of type I collagen have been the subject of intense investigation. Recently, several laboratories have also initiated studies on the bone sialoprotein gene. The following discussion will focus on the osteocalcin gene, which contains the best-understood osteoblast-specific promoter. Recent developments in our understanding of transcriptional control of the bone sialoprotein gene will also be briefly outlined. The type I collagen genes, which are subject to complex controls in a number of tissues in addition to bone, have been recently reviewed (Bornstein, 1996; Dodig et al., 1996b) and will not be discussed in this article.
Transcriptional Regulation of the Osteocalcin Gene
Of the major osteoblast-related gene products, osteocalcin exhibits the most selective pattern of expression; it is synthesized only by mature osteoblasts, odontoblasts, and cementoblasts (Bronckers et al., 1987) . Thus, control mechanisms governing its transcription are likely to include tissue-specific signals. Although the function of this y-carboxyglutamic acid-containing protein is not completely understood, gene knockout experiments suggest a role in bone turnover (Ducy et al., 1996) . The first evidence that the osteocalcin gene promoter contained sufficient information to confer tissue-specific expression came from studies with transgenic animals. When 3.9 kb of untranscribed 5 sequence from the human osteocalcin promoter linked to the reporter gene, chloramphenicol acetyltransferase, was introduced into transgenic mice, selective expression was observed in osteoblasts (Kesterson et al., 1993) . This promoter region, therefore, contains sequences necessary for bone-specific expression. In recent years, investigators have studied the proximal promoter extensively, with the goal of identifying sequence elements necessary for basal and osteoblast-specific expression. These studies followed (Lian et al., 1989) . Also included is a typical TATA box at -26 nt which serves as a binding site for the RNA polymerase-1l-containing transcription initiation complex common to most eucaryotic promoters. Of these known transcription factor binding sites, particular attention has been paid to the VDRE and related AP-1 sites, E-boxes, and the MSX-I site. The osteocalcin gene was the first shown to be directly regulated by the steroid hormone, 1,25-dihydroxyvitamin D3, and was used to define the first functional VDRE (Kerner et al., 1989; Markose et al., 1990) . The intracellular mechanism used by the 1,25-dihydroxyvitamin D3:receptor complex to stimulate osteocalcin transcription and the interaction of this complex with other transcription factors has been recently reviewed (Blanco et al., 1995; Stein et al., 1996) . Species differences have also been observed; acute 1,25-dihydroxyvitamin D3 treatment induces osteocalcin in rat and human cells and reduces osteocalcin in mouse cells (Lian et al., 1997) . This difference is explained by sequence differences in the VDRE-containing region of mouse osteocalcin promoter that render it unresponsive to hormone and by indirect effects of 1,25-dihydroxyvitamin D3 on the transcription factor, Osf2 (see below) (Clemens et al., 1997; . The AP-I sites bind members of the fos/jun family of transcription factors. Although they are not involved in the osteoblast-specific expression of the osteocalcin gene, AP-l sites may be important for suppression of transcription during the proliferative phase of osteoblast development and complement the activity of osteoblastspecific factors to permit transcription after cell growth arrest (McCabe et al., 1995; Stein et al., 1996) . Thus, c-fos and c-jun are expressed at high levels during the proliferative phase and decrease with cell growth arrest and differentiation, while fra-l and junB increase or remain at high levels during differentiation. Consistent with the hypothesis that c-fos may suppress osteocalcin transcription during the proliferative phase, overexpression of this protein by transfection of ROS 17/2.8 cells with a cfos expression vector inhibits osteocalcin expression (Schule et al., 1990) .
The presence of two E-box sequences within the proximal osteocalcin promoter suggested a possible role of bHLH transcription factors in osteoblast differentiation analogous to the myoD family of factors in muscle formation. Previous studies had, in fact, detected several non-tissue-specific bHLH proteins in osteoblasts and showed that they can be regulated by calcitropic factors (Ogata and Noda, 1991; Murray et al., 1992 Murray et al., , 1993 Ogata et al, 1993; Benson et at., 1995) . In addition, forced expression of Id 1, an inhibitory bHLH protein known to interfere with the activity of tissue-specific bHLH proteins in other systems (Benezra et al., 1990) , was reported as partially blocking osteoblast differentiation and osteocalcin promoter activity (Murray et al., 1992; Tamura and Noda, 1994) . Mutagenesis of the downstream E-box (designated OCEI) at nucleotide -102 reduced osteocalcin promoter activity in ROS 17/2.8 cells by 50%. Furthermore, an uncharacterized putative bHLH protein present in nuclear extracts from osteosarcoma cells specifically bound this E-box. Binding activity which was low in undifferentiated mesenchymal cells was reported to be strongly induced by (Tamura and Noda, 1994) . However, more recent studies showed that the nuclear factor binding to OCEI is widely distributed in many non-osteogenic tissues and cell lines and has minimal transcriptional activity when placed 5 to a minimal mouse osteocalcin promoter .
Furthermore, stable transfection of MC3T3-EI mouse pre-osteoblast cells with the rat osteocalcin promoter containing a mutation in OCEI did not affect the developmental upregulation of this promoter as cells differentiated in culture (Quarles et al., 1997) . Thus, bHLH proteins are not likely to play a major role in the osteoblastspecific expression of the osteocalcin gene, at least in cultured cells. However, this class of factors may be involved in earlier steps of bone formation For example, during development, the recently discovered bHLH factor, scleraxis, is expressed at high levels within mesenchymal precursors of the axial and appendicular skeleton in a pattern that pre-figures cartilage anlage formation. Scleraxis levels then decline prior to overt cartilage formation and are not subsequently detected in osteoblasts (Cserjesi et al., 1995) . Thus, scleraxis or related factors may be involved in the early commitment of cartilage progenitors.
As noted above, homeobox genes play an important role in the specification of skeletal structures. The MSX genes (MSX-1 and MSX-2) have demonstrated roles in craniofacial and tooth development. Furthermore, mutations in the MSX-2 locus cause the autosomal-dominant disease, cranial synostosis (labs et al., 1993; Satokata and Maas, 1994; Chen Y, et al., 1996) . For these reasons, the presence of an MSX site in the osteocalcin promoter was of particular interest. MSX-2 mRNA is preferentially expressed in several osteoblast cell lines and primary cultures, while little or no message is detected in several types of non-osteoblastic mesenchymal cells (Hodgkinson et at., 1993; Towler et al., 1994; Heinrichs et al., 1995 (Towler et al., 1994 (Dodig et al., 1996a) .
To gain a more complete understanding of gene expression in bone, Ducy and Karsenty initiated a series of investigations to examine, systematically, the proximal 1.3 kb of the mouse osteocalcin promoter for osteoblast-specific elements . Murine and rodent osteocalcins are encoded in two genes. In mice, osteocalcin genes 1 and 2 are contained in a gene cluster which also contains a third member, osteocalcin-related gene, which is expressed only in the kidney (Desbois et at., 1994) . Systematic deletion analysis of the osteocalcin gene 2 promoter in ROS 17/2.8 cells revealed no major loss of activity between -1300 and -147 bp from the transcription start site . The -147 promoter retained information necessary for osteoblastspecific expression, since it was expressed at high levels in ROS17/2.8 cells, but showed low to undetectable activity in C2/C12 myoblasts, F9 teratocarcinoma cells, and S194 myeloma. Further deletion to -34 bp completely abolished promoter activity. DNase I protection assays with ROS 17/2.8 nuclear extracts and the -147 promoter revealed three major protected regions, designated osteoblast-specific element 1 (OSE1) between -64 and -47 nt, OSE2 between -146 and -132 nt, and OCEl (which contains the E-box described above) between -110 and -83 nt. Gel retardation assays with double-stranded oligonucleotides containing each sequence and nuclear extracts from ROS cells and primary mouse osteoblasts revealed that both OSE I and OSE2 specifically bound nuclear factors, designated osteoblast-specific factor 1 (Osfl) and Osf2, that were selectively expressed in osteoblast-like cells. In contrast, OCEI bound a factor or factors expressed in a wide variety of cell types. Deletions in the -147 bp promoter that removed OSE2 and OSEl drastically reduced promoter activity, while OCEl deletion was without effect. Furthermore, multiple copies of either OSEl or OSE2 selectively stimulated activity of the minimal -34 bp promoter in osteosarcoma cells (greater than 200-fold stimulation), but not in C2/C12 or F9 cells, while minimal activity was detected with multimers of the OCEI sequence. Mutational analysis defined the minimal OSE2 sequence as CCAACCAC. This study provided the first strong functional evidence that osteoblast-specific enhancer sequences were present in the osteocalcin promoter.
The initial clue to the identification of the transcription factor binding OSE2 came from the laboratories of Stein and Lian, who had previously identified two sequences between -605 and -599 nt and -459 and -434 nt in the rat osteocalcin promoter that specifically bound osteoblast nuclear proteins. The factor binding these two regions was called nuclear matrix protein 2 (NMP2), because it could be extracted from this nuclear fraction.
The NMP2 component interacting with the -605 to -599 region was detected in osteoblast-like cells, but not hepatoma, promyelocytic leukemia, or cervical carcinoma cells (Bidwell et al., 1993 . Although the two upstream NMP2 binding sites of the rat osteocalcin promoter served as the basis for the first identification of AML/runt domain transcription factors in bone, to date neither site has been shown to have functional activity in stimulating osteocalcin promoter activity. In the mouse promoter, the most 5' site between -608 and -602 nt is not necessary for osteoblast-specific activity in vivo (Frendo et al., 1998 (Sasaki et al., 1996) .
Definitive identification of the AML-like protein in osteoblasts was recently provided by the Karsenty labora-tory . Using low-stringency hybridization of an osteoblast cDNA library with a Cbfal runt domain probe, they isolated a cDNA, sequenced it, and showed it to be identical in its 3 end to Cbfal (AML3), a molecule originally cloned from a T-cell library. The protein-coding portion of this sequence contains both the proline/serine/threonine-rich and runt domains of Cbfal. More detailed analysis identified a 19-amino-acid N-terminal region in the Osf2/Cbfal sequence cloned from osteoblasts that was not reported in the original Cbfal cDNA (Thirunavukkarasu et al., 1998) . Extensive structure/function analysis of Osf2/Cbfa 1 identified several domains necessary for transcriptional activity, including a myc-related nuclear localization signal, three transcriptional activation domains, and a repression region. Osf2/Cbfa I has several properties expected of an osteoblast-specific transcriptional regulator, including ability to activate the osteocalcin and osteopontin promoters through an AML sequence, selective expression in osteoblasts and osteosarcoma cells, upregulation in mesenchymal cells after induction of osteoblast differentiation with BMPs, and, most importantly, ability to induce multiple osteoblast marker genes lproc I(I) collagen, osteopontin, bone sialoprotein, and osteocalcinl when transfected into mesenchymal cell lines such as C3HlOTl/2 cells or undifferentiated murine MC3T3EI pre-osteoblast cells. In addition, blocking Osf2/CbfaI expression with antisense oligonucleotides inhibited proc-I(I) collagen, osteopontin, and osteocalcin expression and mineralized nodule formation (Banerjee et al., 1997; Ducy et al., 1997) . Of further interest, binding sites for Cbfal were detected in promoter regions of osteoblast marker genes, although it has not yet been demonstrated that all of these sites are functional. In fact, Osf2/Cbfal may actually regulate some osteoblast-related genes through an indirect mechanism (see below).
A final intriguing property of AML family members is their ability to interact with the nuclear matrix, a filamentous ribonucleoprotein network thought to provide the underlying structure for higher-order nuclear organization into RNA polymerase 11-containing transcription foci (Nickerson et at., 1995) . A recent study by Zeng and coworkers identified a 31-amino-acid region in AMLIB necessary for nuclear matrix binding that could be distinguished from the DNA binding domain (Zeng et al., 1997 While it is not clear that Osf2/Cbfa I alone can induce the full repertoire of osteoblast activities in mesenchymal cells (i.e., direct induction of all known markers and formation of a mineralized ECM), this molecule clearly is a major determinant of the osteoblast phenotype. In situ hybridization studies of developing mouse embryos first detected Osf2/Cbfal mRNA in mesenchymal condensations of the axial and appendicular skeleton and skull on embryonic day 12.5 . A similar pattern of 3-galactosidase expression was found in transgenic animals containing a LacZ insert in the CBFAI locus (Otto et al., 1997) . The Osf2/Cbfal-positive cells at this stage also contain markers for initial cartilage condensations which suggest that they represent a common precursor for both chondrocytes and osteoblasts. At later times (embryonic days 14.5 and 16), Osf2/Cbfal is found only in osteoblast precursors.
In the same exciting issue of the journal, Cell, that reported the cloning of Osf2/Cbfa 1, two papers described the phenotype of CBFAI-deficient mice (Komori et al., 1997; Otto et al., 1997) , and a third demonstrated that mutations in the human gene cause the genetic disorder, cleidocranial dysplasia (Otto et al., 1997) . CBFAI-null mice were generated by homologous recombination, and both heterozygous and homozygous animals were found to have severe skeletal abnormalities. (Lee et al., 1997; Otto et al., 1997 (Bianco et at., 1991; Chen et at., 1993; MacNeil and Somerman, 1993; Bellahcene et al., 1996) . The BSP gene has been cloned from rat (Li and Sodek, 1993) , mouse (Benson et al., 1997) , human (Kerr et al., 1993; Kim et al., 1994) , and avian species (Yang and Gerstenfeld, 1997) . An approximately 2.7-kb sequence of the rat BSP promoter driving expression of a firefly luciferase reporter gene was analyzed in transgenic animals and was shown to be selectively expressed in bone osteoblasts, with negligible expression in the kidney, liver, stomach, intestine, and spleen (Chen J, et al., 1996) . Thus, important elements for osteoblast-selective expression are contained in this promoter region. Inspection of the proximal BSP promoter from mammalian species reveals a high degree of sequence conservation, particularly in the first approximately 370 nt upstream from the transcription start site (ca. 75% sequence identity across rat, mouse, and human promoters). This region contains a number of previously characterized DNA sequences, including an inverted TATA box with overlapping VDRE, a CCAAT box, a type 11 collagen-like silencer, and putative binding sites for the transcription factors CREBP (cAMP response element binding protein), NFKB, and fos/jun (AP-1), as well as two homeobox domains (MSX-2 and Engrailed-1) (Sodek et at., 1996; Yang and Gerstenfeld, 1997) . The VDRE and a distal glucocorticoid regulatory element have both been shown to have modest activity in vivo and in cell culture Sodek et al., 1995) . The chicken BSP promoter is also stimulated approximately five-fold by PTH, and this response is mediated by a CRE half-site (Yang and Gerstenfeld, 1996) . Although the chicken promoter shares less overall homology with mammalian BSP promoters, many of the above-listed regulatory elements are conserved, including the two homeobox sites and the collagen silencer region, suggesting that they have important roles in regulation (Yang and Gerstenfeld, 1997) .
Only recently has substantial progress been made in the functional definition of specific elements in the BSP promoter necessary for osteoblast-specific expression. Initial studies in which 2.7 kb of the rat promoter was transiently transfected into osteoblast-like vs. fibroblastic cells revealed little preferential expression in osteoblasts (Sodek et at., 1994) . More recent studies with a 1.2-kb fragment of the chicken promoter showed preferential expression in osteoblasts and cephalic chondrocytes when compared with skin fibroblasts (Yang and Gerstenfeld, 1997) . Some of this specificity was attributed to a suppression of promoter activity in fibroblasts, possibly via the collagen II silencer in the region between -966 and -949 bp. Preliminary studies from the author's laboratory show approximately 20-fold higher expression of a 2.5-kb fragment of the mouse BSP promoter in osteoblasts relative to C2/C12 myoblasts, 3T3-L1 adipocytes, F9 teratocarcinoma cells, and S194 leukemia cells (Benson et al., 1997) . Deletion analysis revealed much of the tissue specificity to reside in a region between -173 and -334 nt upstream from the transcription start site. Deletion of the region containing the collagen II silencer did not increase promoter activity in non-bone cells. Of further interest, although consensus binding sites for AML family members are present in the BSP promoter from all species examined, none is contained in the -173 to -334 region. This suggests that the induction of BSP mRNA by Osf2/Cbfal, noted above , may be through an indirect mechanism.
Extracellular Matrix Regulation of Osteoblast-specific Gene Expression
The extracellular matrix (ECM) plays an essential if often overlooked role in osteoblast differentiation. As a cell primarily devoted to matrix production, the osteoblast must have the ability to monitor the composition of the ECM it is secreting as well modify matrix production to accommodate the changing mechanical needs of bone. It is not known how this is accomplished. However, there is now strong evidence that osteoblast differentiation and collagen matrix secretion are closely linked. An appreciation for the significance of the ECM in osteoblast function may be gained from an examination of the requirement for ascorbic acid (AA, reduced vitamin C) in osteoblast differentiation. AA is an essential co-factor for hydroxylation of procollagen chains, a necessary step for triple helix formation, secretion, and collagen fibril assembly. Thus, in vitamin C deficiency, collagen matrix production is essentially blocked. In vivo, both bone formation and osteoblast differentiation, as assessed by expression of osteocalcin and alkaline phosphatase mRNAs, are severely reduced in animals on vitamin-Cdeficient diets (Togari et al., 1995; Mahmoodian et al., 1996) . This requirement is also seen in vitro, where AA is essential for differentiation and mineralization of primary osteoblast cultures and nontransformed osteoblast-like cell lines such as murine MC3T3-E1 cells (Gerstenfeld et al., 1987; Owen et al., 1990; Franceschi and Iyer, 1992; Ibaraki et al., 1992; Quarles et al., 1992; McCauley et al., 1996) . AA responsiveness is a unique property of nontransformed cells and is not observed in osteosarcoma cell lines such as the ROS 17/2.8 cells used in many of the studies described above to characterize the osteocalcin promoter. These cells express high levels of osteoblast markers in the absence of AA, which suggests either that an important level of regulation has been lost in this osteosarcoma cell line or that ROS17/2.1 cells have progressed beyond the point in the osteoblast lineage where ECM synthesis is required for phenotypic expression. Studies from the author's laboratory have demonstrated that actions of AA on osteoblast differentiation are mediated by the collagenous matrix (Franceschi and lyer, 1992; Franceschi et al., 1994) . Disruption of matrix secretion with specific inhibitors or enzymatic digestion of secreted collagen blocks the induction of osteoblast-related genes. A similar requirement for collagen synthesis was recently demonstrated in retinoic-acid-treated ROB-C26 cells, a multipotential mesenchymal cell line (Shi et al., 1996) .
Studies on the genetic disease osteogenesis imperfecta (01) further support the importance of the ECM environment in osteoblast function. The majority of 01 mutations are in glycines that occupy every third residue in the helical region of type I collagen or are deletions in the triple helical domain. The consequences of these mutations may, to various degrees, be similar to the situation encountered in AA deficiency: Procollagen triplehelix structure is destabilized with accompanying decreased rates of secretion, processing and cross-linking, and abnormal fibril assembly. These defects would, in turn, compromise the ability of cells to differentiate normally. In fact, osteopenia due to reduced extracellular matrix synthesis is a hallmark of 01, and osteoblasts cultured from 01 patients exhibit reduced synthesis of collagen and proteoglycan (Fedarko et al., 1992 (Fedarko et al., , 1996 . To examine more directly the effect of abnormal collagen structure on osteoblast differentiation, Wenstrup and coworkers created MC3T3-E I cell lines that stably expressed a human proox1(l) collagen minigene with a truncated triple helical domain known to cause an 01 phenotype in transgenic mice (Wenstrup et al., 1996) . As predicted from studies with AA-deficient cells, osteoblasts containing this abnormal collagen exhibited rapid matrix turnover, severely abnormal collagen fibrillogenesis, and decreased levels of alkaline phosphatase and bone sialoprotein. However, osteocalcin levels were actually elevated, indicating that this matrix abnormality affects osteocalcin differently from other osteoblast markers.
More recent studies focused on the relationship between matrix synthesis and induction of osteoblastspecific gene expression, with the well-characterized mouse osteocalcin gene 2 as a model (Xiao et al., 1997) . ECM synthesis increased promoter activity approximately 20-fold in MC3T3-E1 cells. Significantly, this response was shown to require OSE2, the downstream promoter binding site for the transcription factor Osf2/Cbfa 1.
Mutation or deletion of this element abolished activity. Furthermore, OSE2 oligomers in the absence of other promoter elements were able to confer matrix responsiveness on a -34-nt minimal osteocalcin promoter construct. Although deletion analysis suggested that other upstream regions of the osteocalcin promoter between -657 and -147 may also contribute to ECM responsiveness, the downstream OSE2 site is clearly essential, because a point mutation in this element abolished the AA responsiveness of a -657 promoter construct. AA treatment was also accompanied by a five-fold increase in the binding of Osf2/Cbfal to OSE2. Thus, ECM synthesis stimulates osteoblast-specific transcriptional activity in part by activating/upregulating the tissue-specific transcription factor, Osf2/Cbfa 1. We do not currently know if this mechanism explains the upregulation of other genes by AA. However, like osteocalcin, the bone sialoprotein promoter is upregulated by AA and may be subjected to similar controls (Benson et al., 1997) .
Ongoing studies in the author's laboratory and elsewhere are exploring possible mechanisms to explain how the collagenous ECM can stimulate osteoblast-specific gene expression. Several years ago, we proposed a general model for ECM regulation of osteoblast differentiation in which the matrix was viewed as interacting with the cell surface through specific integrins to initiate intracellular signaling pathways leading to osteoblast-specific gene expression (Franceschi, 1992) . Integrins are the principal mediators of the molecular dialogue between a cell and its ECM environment and are crucial to processes such as tissue morphogenesis, wound healing, and cell migration and attachment (for reviews, see Clark and Brugge, 1995; Gumbiner, 1996 (Roeckel and Krieg, 1994; Sudbeck et al., 1994; Lin et al., 1997) .
Recently, considerable evidence has accumulated ECM f fE DGEA?- (Clark and Brugge, 1995; Gumbiner, 1996) , although those relevant to osteoblast function have not been defined. Also indicated is the physical linkage between integrins and the cytoskeleton via cx-actinin and the actin filaments, which may also control transcription. Not shown is the possible role of nuclear organization in the activation of Osf2/Cbfal. It has been proposed that this factor can associate with the nuclear matrix as well as with AML sites in the osteocalcin promoter, thereby bringing the promoter into contact with the basal transcription initiation complex. (Takeuchi et al., 1996) .
These responses appear to require focal adhesion kinase and the MAP kinase pathway, because selective inhibition of either of these intermediates blocks alkaline phosphatase induction (Takeuchi et al., 1997 increasing protein levels. In a related study, overexpression of the c.2 integrin subunit in primary calvarial osteoblast cells also greatly increased osteocalcin promoter activity (Zimmerman et al., 1997) . Recent preliminary results from the author's laboratory indicate that Osf2/Cbfa I is phosphorylated by MAP kinases and that this modification stimulates transcriptional activity (Xiao et al., 1998b) .
Taken together, these results strongly support a model in which an CX2031 integrin:type I collagen interaction is necessary for phosphorylation and activation of osteoblastspecific transcription factors like Osf2/Cbfal present in committed osteoprogenitor cells. There are several examples of type I collagen: oL2A integrin interactions being important in the regulation of other cellular activities, such as activation of collagenase (Riikonen et al., 1995) , stimulation of collagen gel contraction (Schiro et al., 1991) , and kidney tubule formation (Schwimmer and Ojakian, 1995) , although in no case has the entire integrin-mediated pathway been delineated. Clearly, a major direction for future research will be to identify the signal transduction pathway linking integrin:ECM binding to changes in osteoblast-specific gene expression and to determine how this pathway is regulated by changes in matrix synthesis and turnover, mechanical loading of bone, and the hormonal milieu. Is the Tooth a Kind of Bone?
At the molecular level, dentin and cementum share many similarities with bone, including the presence of a mineralized type I collagen matrix and noncollagenous proteins such as osteocalcin, bone sialoprotein, alkaline phosphatase, and BMPs (MacNeil and Somerman, 1993; Lesot et al., 1994) . In fact, because no unique markers have been identified to distinguish it from bone, it has been proposed that the cementoblast may actually be a specialized type of osteoblast (MacNeil et al., 1998 Initial reports on tooth formation in Osf2/Cbfal knockout mice suggest the involvement of this factor in tooth morphogenesis, but it remains to be determined if it functions similarly in bones and teeth. Elucidation of the regulatory controls for multiple odontoblast-related genes will be required to discriminate between general and tooth-specific gene regulatory mechanisms.
